A randomized trial comparing preservation of function status after either Medpulser electroporation with intratumoral bleomycin therapy [Selective Electrochemical Tumor Ablation, SECTA; Inovio Biomedical Corporation] or surgery in patients with locally recurrent or second primary squamous cell carcinoma of the anterior oral cavity, soft palate, or tonsil that have failed primary curative therapy.

Trial Profile

A randomized trial comparing preservation of function status after either Medpulser electroporation with intratumoral bleomycin therapy [Selective Electrochemical Tumor Ablation, SECTA; Inovio Biomedical Corporation] or surgery in patients with locally recurrent or second primary squamous cell carcinoma of the anterior oral cavity, soft palate, or tonsil that have failed primary curative therapy.

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Bleomycin (Primary)
  • Indications Head and neck cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 29 Sep 2017 Status changed from suspended to withdrawn prior to enrolment.
    • 24 Jul 2012 Interim results were presented at the 8th International Conference on Head and Neck Cancer in Toronto.
    • 23 Jul 2012 Primary endpoint 'EORTC-Quality-of-Life-Questionnaire' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top